Press Release Archive
Press Releases
April 2023
04.27.2023 Vaccines U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children 04.27.2023 Corporate Finance Pfizer Announces 2023 Shareholder Meeting Preliminary Results 04.26.2023 Financial Finance Pfizer Declares Second-Quarter 2023 Dividend 04.13.2023 Financial Finance Pfizer Invites Shareholders to Attend Virtual-Only 2023 Annual Meeting of Shareholders on April 27 04.04.2023 Medicines FDA Accepts Pfizer’s Supplemental New Drug Applications for BRAFTOVI + MEKTOVI
March 2023
03.21.2023 Financial Finance Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts 03.16.2023 Medicines Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer 03.16.2023 Covid-19 Medicines FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™ 03.14.2023 Vaccines Covid-19 Vaccines Pfizer and BioNTech Receive U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years 03.13.2023 Financial Investments Pfizer Invests $43 Billion to Battle Cancer 03.10.2023 Medicines Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval 03.01.2023 Vaccines Covid-19 Vaccines Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years
Media Resources & Contact Information
Anyone may view our press releases, press statements, and press kits.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.